Drugs / Brassica juncea
Brassica juncea
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00547547 | Apr 2006 → Aug 2012 | cancer of unknown primary site | City of Hope Medical Center | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Brassica juncea | “To determine the maximum tolerated dose of high-selenium Brassica juncea (BJ-Se) and capecitabine when administered in combination with irinotecan hydrochloride in patients...” NCT00547547 ↗ |
| Known as | BJ-Se | “To determine the maximum tolerated dose of high-selenium Brassica juncea (BJ-Se) and capecitabine when administered in combination with irinotecan hydrochloride in patients...” NCT00547547 ↗ |
| Known as | high-selenium Brassica juncea | “To determine the maximum tolerated dose of high-selenium Brassica juncea (BJ-Se) and capecitabine when administered in combination with irinotecan hydrochloride in patients...” NCT00547547 ↗ |
| Route | Oral | “Patients receive oral BJ-Se on days -7 to 21 in course 1 and on days 1-21 in all other courses.” NCT00547547 ↗ |